Share on StockTwits

Lannett Company (NYSE:LCI) Director Paul Taveira sold 1,000 shares of Lannett Company stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $46.94, for a total value of $46,940.00. Following the completion of the transaction, the director now directly owns 15,625 shares of the company’s stock, valued at approximately $733,438. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

A number of analysts have recently weighed in on LCI shares. Analysts at Canaccord Genuity initiated coverage on shares of Lannett Company in a research note on Tuesday, May 6th. They set a “buy” rating and a $55.00 price target on the stock. Analysts at Zacks downgraded shares of Lannett Company from an “outperform” rating to a “neutral” rating in a research note on Wednesday, April 9th. They now have a $37.80 price target on the stock. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Lannett Company currently has a consensus rating of “Buy” and an average target price of $42.95.

Shares of Lannett Company (NYSE:LCI) opened at 47.42 on Friday. Lannett Company has a 52-week low of $10.18 and a 52-week high of $48.613. The stock has a 50-day moving average of $40.77 and a 200-day moving average of $37.38. The company has a market cap of $1.687 billion and a price-to-earnings ratio of 42.64.

Lannett Company (NYSE:LCI) last released its earnings data on Wednesday, May 7th. The company reported $0.63 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.60 by $0.03. The company had revenue of $80.00 million for the quarter, compared to the consensus estimate of $84.50 million. During the same quarter last year, the company posted $0.14 earnings per share. Lannett Company’s revenue was up 105.0% compared to the same quarter last year. Analysts expect that Lannett Company will post $1.75 EPS for the current fiscal year.

Lannett Company, Inc is engaged in developing, manufacturing, marketing and distributing generic versions of branded pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.